JPM-OEt (C09-1141-002)

JPM-OEt is a broad spectrum cysteine cathepsin inhibitor. JPM-OEt binds covalently in the active site, and irreversibly inhibits the cysteine cathepsin family. Antitumor activity.In VivoJPM-OEt (50 mg/kg; i.p.; daily for 30 days) reduces tumor cathepsin B activity significantly . JPM-OEt (50 mg/kg; i.p.; twice daily for 4 weeks) leads to tumor regression in the RIP1-Tag2 (RT2) mouse model of pancreatic islet cell tumorigenesis. JPM-OEt (50 mg/kg; i.p.; daily from 63 to 98 days) causes a significant delay in the increase of tumour burden during the first 2 weeks of treatment. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female mice of a transgenic mouseDosage: 50 mg/kg Administration: i.p.; daily from 63 to 98 days Result: Caused a significant delay in the increase of tumour burden during the first 2 weeks of treatment. However, on days 84, 91 and 98 no significant differences between both groups could be detected.Form:Solid. Specification: 0.99 Molecular Formula: C20H28N2O6 Molecular Weight: 392.45